Aclarion Logs 196% Scan Volume Surge, CEO Buys Shares and Unveils $2.5M Buyback
Aclarion reported a 196% year-over-year increase in Q1 2026 Nociscan platform scans, signaling strong adoption of its AI chronic back pain solution. CEO Ness Brent purchased 6,289 shares, raising his stake to 6,300 shares, as the company maintains no debt, funds operations into 2027 and launches a $2.5 million buyback.
1. Operational Growth Propels Nociscan Adoption
Aclarion’s Nociscan platform recorded a 196% year-over-year increase in scan volume during Q1 2026, reflecting accelerated uptake by healthcare providers seeking AI-driven chronic back pain diagnostics.
2. Insider Purchase Signals Confidence
CEO Ness Brent acquired 6,289 additional shares, lifting his total ownership to 6,300 shares and underscoring executive belief in the company’s strategic direction.
3. Robust Balance Sheet and Buyback Program
The company holds no debt, projects cash to fund operations into 2027 and has initiated a $2.5 million share repurchase program to support its stock value.
4. CLARITY Trial Expansion Advances Clinical Research
ACON is ramping enrollment for its CLARITY Trial by adding its first private practice site in Los Angeles, aiming to validate its AI platform in broader clinical settings.